Head-to-head · WeighScore
Blue Haven RX vs Omada Health
The verdict
Omada Health takes it — 55.6/100 to 50.8/100.
Omada Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Omada Health is a virtual care company offering behavior-change programs for weight health, diabetes and hypertension, distributed through employers and health plans.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Blue Haven RX | Omada Health |
|---|---|---|
| WeighScore | 50.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #489 | #435 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #489 · C
Strengths
- Flat all-inclusive pricing — consult, prescription, medication and free shipping
- Not charged until a US-licensed physician approves your prescription
- Named operating entity disclosed (Eternum Health LLC)
- Both compounded semaglutide and tirzepatide listed as in-stock
Where it loses points
- Mixed third-party reviews — Trustpilot complaints on customer service and dosing
- Doesn't publish the states it serves or specific pharmacy partners
- No clearly verifiable accreditation badge (e.g. LegitScript) on the site
- Compounded semaglutide and tirzepatide only — no brand-name or oral options
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.